微粒化非诺贝特治疗血脂异常的疗效与耐受性研究

A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia

目的 观察微粒化非诺贝特对低密度脂蛋白 胆固醇 (LDL C)水平轻中度升高或高密度脂蛋白 胆固醇 (HDL C)水平降低患者的疗效。方法 1998～ 1999年间在全国 16个城市 ,2 35 8例IIa、IIb和IV型高脂血症患者 ,服用微粒化非诺贝特 (微粒化力平之 ) 2 0 0mg/d ,共 8周。治疗前后测定血脂及安全参数进行分析。结果 微粒化非诺贝特可使HDL C升高近 13% ,其升高程度与HDL C基线水平呈负相关。全组中 837例患者基线HDL C <1 0mmol/L ,其中 5 10例 (6 0 9% )在治疗 8周时升至 >1 0mmol/L(平均 1 3mmol/L)。此外 ,治疗后全组LDL C平均降低 15 9% ,其疗效与基线LDL C水平呈正相关。治疗过程中患者对药物的耐受性较好。结论 短期使用微粒化非诺贝特除具有贝特类药物所共有的显著降低甘油三酯水平作用外 ,同时还能显著升高HDL C ,显著降低轻、中度升高的LDL C水平。

Objective To demonstrate the clinical efficacy of micronized fenofibrate on mildly moderately elevated LDL C level and reduced HDL C level Methods During 1998 1999, 2 358 patients with type IIa, IIb and IV hyperlipidemia in 16 cities in China were monitored They were treated with micronized fenofibrate (micronized lipathyl) 200 mg daily for 8 weeks Lipid levels before and after treatment were measured and analysed Results Micronized fenofibrate significantly increased HDL C level by 12 7%, the effect being inversely correlated with the baseline HDL C level In total patient population, baseline level of HDL C<1 0mmol/L(40 mg/dl) were found in 837 patients, in whom the increment in level of HDL C to >1 0mmol/L with a mean of 1 3mmol/L(50mg/dl)was observed in 510 (60 9%) after 8 week therapy Furthermore, the mean LDL C level reduced by 15 9% following 8 week treatment of micronized fenofibrate,an effect positively correlated with baseline LDL level In general, the drug was well tolerated in all the patients Conclusion Short term treatment of micronized fenofibrate in patients with dyslipidemia significantly increases HDL C level and reduces mild moderately elevated LDL C As expected, it also reduces triglyceride levels